239 related articles for article (PubMed ID: 33217500)
1. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome.
Teriaca MA; Loi M; Suker M; Eskens FALM; van Eijck CHJ; Nuyttens JJ
Radiother Oncol; 2021 Feb; 155():232-236. PubMed ID: 33217500
[TBL] [Abstract][Full Text] [Related]
2. Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer.
Jung JH; Song C; Jung IH; Ahn J; Kim B; Jung K; Lee JC; Kim J; Hwang JH
Front Oncol; 2022; 12():1050070. PubMed ID: 36620548
[TBL] [Abstract][Full Text] [Related]
3. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study.
Suker M; Nuyttens JJ; Groot Koerkamp B; Eskens FALM; van Eijck CHJ
J Surg Oncol; 2018 Nov; 118(6):1021-1026. PubMed ID: 30259526
[TBL] [Abstract][Full Text] [Related]
4. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
5. Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-progressive locally advanced pancreatic cancer, after induction chemotherapy with (modified)FOLFIRINOX - The LAPC-2 trial.
van 't Land FR; Latifi D; Moskie M; Homs MYV; Bosscha K; Bonsing BA; Mieog SD; van der Harst E; Coene PLO; Wijsman JH; van der Schelling GP; Groot Koerkamp B; Nuyttens JJ; van Eijck CHJ;
Radiother Oncol; 2023 Jun; 183():109541. PubMed ID: 36813171
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial).
Suker M; Nuyttens JJ; Eskens FALM; Haberkorn BCM; Coene PLO; van der Harst E; Bonsing BA; Vahrmeijer AL; Mieog JSD; Jan Swijnenburg R; Roos D; Koerkamp BG; van Eijck CHJ
EClinicalMedicine; 2019 Dec; 17():100200. PubMed ID: 31891135
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer.
Chen Z; Lv Y; Li H; Diao R; Zhou J; Yu T
Medicine (Baltimore); 2021 Jan; 100(3):e24068. PubMed ID: 33546009
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience.
Lee J; Lee JC; Gromski MA; Kim HW; Kim J; Kim J; Hwang JH
Medicine (Baltimore); 2018 Dec; 97(50):e13592. PubMed ID: 30558029
[TBL] [Abstract][Full Text] [Related]
10. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
[TBL] [Abstract][Full Text] [Related]
11. Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only: Multicenter Propensity Score-matched Analysis.
Brada LJH; Daamen LA; Magermans LG; Walma MS; Latifi D; van Dam RM; de Hingh IH; Liem MSL; de Meijer VE; Patijn GA; Festen S; Stommel MWJ; Bosscha K; Polée MB; Nio YC; Wessels FJ; de Vries JJJ; van Lienden KP; Bruijnen RC; Busch OR; Koerkamp BG; van Eijck C; Molenaar QI; Wilmink HJW; van Santvoort HC; Besselink MG;
Ann Surg; 2021 Nov; 274(5):729-735. PubMed ID: 34334641
[TBL] [Abstract][Full Text] [Related]
12. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial.
Hill CS; Rosati L; Wang H; Tsai HL; He J; Hacker-Prietz A; Laheru DA; Zheng L; Sehgal S; Bernard V; Le DT; Pawlik TM; Weiss MJ; Narang AK; Herman JM
Pract Radiat Oncol; 2022; 12(6):511-523. PubMed ID: 35306231
[TBL] [Abstract][Full Text] [Related]
13. A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
Shaib WL; Hawk N; Cassidy RJ; Chen Z; Zhang C; Brutcher E; Kooby D; Maithel SK; Sarmiento JM; Landry J; El-Rayes BF
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):296-303. PubMed ID: 27475674
[TBL] [Abstract][Full Text] [Related]
14. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
[TBL] [Abstract][Full Text] [Related]
15. Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison.
van Veldhuisen E; Vroomen LG; Ruarus AH; Derksen TC; Busch OR; de Jong MC; Kazemier G; Puijk RS; Sorgedrager NS; Vogel JA; Scheffer HJ; van Lienden KP; Wilmink JW; Besselink MG; Meijerink MR
J Vasc Interv Radiol; 2020 Oct; 31(10):1600-1608. PubMed ID: 32861569
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
[TBL] [Abstract][Full Text] [Related]
17. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy.
Hill C; Sehgal S; Fu W; Hu C; Reddy A; Thompson E; Hacker-Prietz A; Le D; De Jesus-Acosta A; Lee V; Zheng L; Laheru DA; Burns W; Weiss M; Wolfgang C; He J; Herman JM; Meyer J; Narang A
Cancer Med; 2022 Apr; 11(7):1659-1668. PubMed ID: 35142085
[TBL] [Abstract][Full Text] [Related]
18. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms.
Brada LJH; Walma MS; Daamen LA; van Roessel S; van Dam RM; de Hingh IH; Liem MLS; de Meijer VE; Patijn GA; Festen S; Stommel MWJ; Bosscha K; Polée MB; Yung Nio C; Wessels FJ; de Vries JJJ; van Lienden KP; Bruijnen RC; Los M; Mohammad NH; Wilmink HW; Busch OR; Besselink MG; Quintus Molenaar I; van Santvoort HC;
J Surg Oncol; 2021 Sep; 124(4):589-597. PubMed ID: 34115379
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.
Lin C; Verma V; Lazenby A; Ly QP; Berim LD; Schwarz JK; Madiyalakan M; Nicodemus CF; Hollingsworth MA; Meza JL; Are C; Padussis J; Grem JL
Am J Clin Oncol; 2019 Oct; 42(10):755-760. PubMed ID: 31513018
[TBL] [Abstract][Full Text] [Related]
20. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma.
Bouchart C; Engelholm JL; Closset J; Navez J; Loi P; Gökburun Y; De Grez T; Mans L; Hendlisz A; Bali MA; Eisendrath P; Van Gestel D; Hein M; Moretti L; Van Laethem JL
Ther Adv Med Oncol; 2021; 13():17588359211045860. PubMed ID: 34691244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]